Press Releases<< Back
AlloSure Featured in Journal of Applied Laboratory Medicine
Lead author Dr.
- Stable, healthy renal transplant recipients have a median AlloSure level of 0.21%.
- 96% of AlloSure results for stable, healthy renal transplant patients are below 1% dd-cfDNA.
- The reference change value RCV(%), for AlloSure is 61. This reference change value defines the relative change, between two sequential results from an individual that may be considered clinically significant.
This reference population was selected from the cohort of subjects enrolled in the DART study (Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients, NCT02424227) Rigorous demonstration of the assay analytical variation of the clinical-grade AlloSure assay used in this study was critical to these findings.
The link to the publication: http://jalm.aaccjnls.org/content/early/2017/03/13/jalm.2016.022731
NOTES FOR CITATION OF PUBLICATION
"Biological Variation of Donor-derived Cell-free DNA in Renal Transplant Recipients: Clinical Implications" by
ABOUT THE JOURNAL OF Applied Laboratory Medicine:
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the
Sasha King, Head of Marketing T: +1 415-287-2393 E: firstname.lastname@example.org
News Provided by Acquire Media